Effects of morphine and NeuroAid on the expression levels of GluN2A and GluN3A in the hippocampus and striatum of rats

Document Type : Original Article

Authors

1 Cognitive and Neuroscience Research Center (CNRC), Amir-Almomenin Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2 Department of Cognitive Neuroscience, Institute for Cognitive Science Studies (ICSS), Tehran, Iran

Abstract

Objective(s): NMDA glutamatergic receptors are heteromeric receptors with various subunits. GluN2A and GluN3A subunits specify the functional heterogeneity of NMDA receptors. These subunits play a key role in the induction of LTP and synaptic plasticity. Note that, the function of NMDA subunits has interaction with the mechanism of morphine. On the other hand, NeuroAid is a Chinese traditional medicine with neuroprotective and anti-apoptotic effects. In this study, we aimed to investigate the effect of morphine and NeuroAid on expression levels of GluN2A and GluN3A in the hippocampus and striatum of rats.
Materials and Methods: Morphine sulfate (increasing doses) and NeuroAid (2.5 mg/kg) were injected intraperitoneally. Real-time PCR was used to assess gene expression.
Results: The results showed that morphine increased the expression of GluN2A in the hippocampus and striatum, while NeuroAid increased the expression of both genes in the hippocampus and decreased the expression of GluN3A in the striatum. NeuroAid increased the expression of GluN3A in the hippocampus and GluN2A in the striatum of morphine-addicted rats.
Conclusion: NeuroAid may have interaction with the effect of morphine on glutamatergic neurotransmission; however, this study is innovative and novel, thus, further studies are needed to better understand the effect of NeuroAid and morphine on hippocampal and striatal glutamatergic neurotransmission.

Keywords


1. Tong G, Takahashi H, Tu S, Shin Y, Talantova M, Zago W, et al. Modulation of NMDA receptor properties and synaptic transmission by the NR3A subunit in mouse hippocampal and cerebrocortical neurons. J Neurophysiol 2008; 99:122-132.
2. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010; 62:405-496.
3. Grand T, Abi Gerges S, David M, Diana MA, Paoletti P. Unmasking GluN1/GluN3A excitatory glycine NMDA receptors. Nat Commun 2018; 9:1-12.
4. Sanz-Clemente A, Nicoll RA, Roche KW. Diversity in NMDA receptor composition: many regulators, many consequences. Neuroscientist 2013; 19:62-75.
5. Zhou C, Sun H, Klein PM, Jensen FE. Neonatal seizures alter NMDA glutamate receptor GluN2A and 3A subunit expression and function in hippocampal CA1 neurons. Front Cell Neurosci 2015; 9:1-11.
6. Sanz-Clemente A, Gray JA, Ogilvie KA, Nicoll RA, Roche KW. Activated CaMKII couples GluN2B and casein kinase 2 to control synaptic NMDA receptors. Cell Rep 2013; 3:607-614.
7. Zhou Y, Takahashi E, Li W, Halt A, Wiltgen B, Ehninger D, et al. Interactions between the NR2B receptor and CaMKII modulate synaptic plasticity and spatial learning. J Neurosci 2007; 27:13843-13853.
8. McQuail JA, Beas BS, Kelly KB, Simpson KL, Frazier CJ, Setlow B, et al. NR2A-containing NMDARs in the prefrontal cortex are required for working memory and associated with age-related cognitive decline. J Neurosci 2016; 36:12537-12548.
9.Lee JH, Wei L, Deveau TC, Gu X, Yu SP. Expression of the NMDA receptor subunit GluN3A (NR3A) in the olfactory system and its regulatory role on olfaction in the adult mouse. Brain Struct Funct 2016; 221:3259-3273.
10. Henson MA, Roberts AC, Perez-Otano I, Philpot BD. Influence of the NR3A subunit on NMDA receptor functions. Prog Neurobiol 2010; 91:23-37.
11. Larsen RS, Corlew RJ, Henson MA, Roberts AC, Mishina M, Watanabe M, et al. NR3A-containing NMDARs promote neurotransmitter release and spike timing-dependent plasticity. Nat Neurosci 2011; 14:338-344.
12. Pachernegg S, Strutz-Seebohm N, Hollmann M. GluN3 subunit-containing NMDA receptors: not just one-trick ponies. Trends Neurosci 2012; 35:240-249.
13. Yuan T, Bellone C. Glutamatergic receptors at developing synapses: the role of GluN3A-containing NMDA receptors and GluA2-lacking AMPA receptors. Eur J Pharmacol 2013; 719:107-111.
14. Ko SW, Wu LJ, Shum F, Quan J, Zhuo M. Cingulate NMDA NR2B receptors contribute to morphine-induced analgesic tolerance. Mol Brain 2008; 1:1-11.
15. Jeziorski M, White FJ, Wolf ME. MK-801 prevents the development of behavioral sensitization during repeated morphine administration. Synapse 1994; 16:137-147.
16. Ma YY, Chu NN, Guo CY, Han JS, Cui CL. NR2B-containing NMDA receptor is required for morphine-but not stress-induced reinstatement. Exp Neurol 2007; 203:309-319.
17. Bajo M, Crawford EF, Roberto M, Madamba SG, Siggins GR. Chronic morphine treatment alters expression of N-methyl-D-aspartate receptor subunits in the extended amygdala. J Neurosci Res 2006; 83:532-537.
18. Le Greves P, Huang W, Zhou Q, Thornwall M, Nyberg F. Acute effects of morphine on the expression of mRNAs for NMDA receptor subunits in the rat hippocampus, hypothalamus and spinal cord. Eur J Pharmacol 1998; 341:161-164.
19. Chan HY, Stanton LW. A pharmacogenomic profile of human neural progenitors undergoing differentiation in the presence of the traditional Chinese medicine NeuroAiD. Pharmacogenomics J 2016; 16:461-471.
20. Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology 2010; 58:987-1001.
21. Quintard H, Borsotto M, Veyssiere J, Gandin C, Labbal F, Widmann C, et al. MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology 2011; 61:622-631.
22. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 2008; 1144:97-112.
23. Laux-Biehlmann A, Mouheiche J, Veriepe J, Goumon Y. Endogenous morphine and its metabolites in mammals: history, synthesis, localization and perspectives. Neuroscience 2013; 233:95-117.
24. Tomazi L, Mello CF, Schoffer AP, Girardi BA, Fruhauf PK, Rubin MA. A Nonrewarding NMDA Receptor Antagonist Impairs the Acquisition, Consolidation, and Expression of Morphine Conditioned Place Preference in Mice. Mol Neurobiol 2017; 54:710-721.
25. Lilius TO, Viisanen H, Jokinen V, Niemi M, Kalso EA, Rauhala PV. Interactions of (2S,6S;2R,6R)-hydroxynorketamine, a secondary metabolite of (R,S)-ketamine, with morphine. Basic Clin Pharmacol Toxicol 2018; 122:481-488.
26. Bannerman DM, Niewoehner B, Lyon L, Romberg C, Schmitt WB, Taylor A, et al. NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J Neurosci 2008; 28:3623-3630.
27. Barria A, Malinow R. Subunit-specific NMDA receptor trafficking to synapses. Neuron 2002; 35:345-353.
28. Milton AL, Merlo E, Ratano P, Gregory BL, Dumbreck JK, Everitt BJ. Double dissociation of the requirement for GluN2B- and GluN2A-containing NMDA receptors in the destabilization and restabilization of a reconsolidating memory. J Neurosci 2013; 33:1109-1115.
29. Lue WM, Huang EY, Yang SN, Wong CS, Tao PL. Post-treatment of dextromethorphan reverses morphine effect on conditioned place preference in rats. Synapse 2007; 61:420-428.
30. Zarrindast MR, Lashgari R, Rezayof A, Motamedi F, Nazari-Serenjeh F. NMDA receptors of dorsal hippocampus are involved in the acquisition, but not in the expression of morphine-induced place preference. Eur J Pharmacol 2007; 568:192-198.
31. Mony L, Zhu S, Carvalho S, Paoletti P. Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines. EMBO J 2011; 30:3134-3146.
32. Mariani RK, Mello CF, Rosa MM, Ceretta AP, Camera K, Rubin MA. Effect of naloxone and morphine on arcaine-induced state-dependent memory in rats. Psychopharmacology (Berl) 2011; 215:483-491.
33. Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur J Neurosci 2011; 33:1351-1365.
34. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004; 91:3-12.
35. Inoue M, Mishina M, Ueda H. Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J Neurosci 2003; 23:6529-6536.
36. Zheng Q, Liu Z, Wei C, Han J, Liu Y, Zhang X, et al. Activation of the D1 receptors inhibits the long-term potentiation in vivo induced by acute morphine administration through a D1-GluN2A interaction in the nucleus accumbens. Neuroreport 2014; 25:1191-1197.
37. Heurteaux C, Widmann C, Moha ou Maati H, Quintard H, Gandin C, Borsotto M, et al. NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovasc Dis 2013; 35 Suppl 1:1-7.
38. Quintard H, Lorivel T, Gandin C, Lazdunski M, Heurteaux C. MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats. Neuroscience 2014; 277:72-86.
39. Lorivel T, Gandin C, Veyssiere J, Lazdunski M, Heurteaux C. Positive effects of the traditional Chinese medicine MLC901 in cognitive tasks. J Neurosci Res 2015; 93:1648-1663.
40. Grosshans DR, Clayton DA, Coultrap SJ, Browning MD. LTP leads to rapid surface expression of NMDA but not AMPA receptors in adult rat CA1. Nat Neurosci 2002; 5:27-33.
41. Baez MV, Oberholzer MV, Cercato MC, Snitcofsky M, Aguirre AI, Jerusalinsky DA. NMDA receptor subunits in the adult rat hippocampus undergo similar changes after 5 minutes in an open field and after LTP induction. PLoS One 2013; 8:e55244.
42. Lee MC, Ting KK, Adams S, Brew BJ, Chung R, Guillemin GJ. Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One 2010; 5:e14123.
43. Kehoe LA, Bernardinelli Y, Muller D. GluN3A: An NMDA receptor subunit with exquisite properties and functions. Neural Plast 2013; 2013:145387.
44. Rozeboom AM, Queenan BN, Partridge JG, Farnham C, Wu JY, Vicini S, et al. Evidence for glycinergic GluN1/GluN3 NMDA receptors in hippocampal metaplasticity. Neurobiol Learn Mem 2015; 125:265-273.
45. Lou W, Zhang X, Hu XY, Hu AR. MicroRNA-219-5p inhibits morphine-induced apoptosis by targeting key cell cycle regulator WEE1. Med Sci Monit 2016; 22:1872-1879.
46. Jalili C, Sohrabi M, Jalili F, Salahshoor MR. Assessment of thymoquinone effects on apoptotic and oxidative damage induced by morphine in mice heart. Cell Mol Biol 2018; 64:33-38.
47. Liu P, Che X, Yu L, Yang X, An N, Song W, et al. Uridine attenuates morphine-induced conditioned place preference and regulates glutamate/GABA levels in mPFC of mice. Pharmacol Biochem Behav 2017; 163:74-82.
48. Wang XF, Zhao TY, Su RB, Wu N, Li J. Agmatine prevents adaptation of the hippocampal glutamate system in chronic morphine-treated rats. Neurosci Bull 2016; 32:523-530.